A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00578825

Enrollment

340

Registered

2007-12-21

Start date

Unknown

Completion date

Unknown

Last updated

2013-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Acute Respiratory Syndrome

Keywords

Severe acute respiratory syndrome

Brief summary

The study aims to examine whether the combination of Lopinavir/Ritonavir plus Ribavirin for treatment of severe acute respiratory syndrome (SARS) is superior to placebo.

Interventions

DRUGLopinavir / Ritonavir plus Ribavirin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Male or female over the age of 18 with a diagnosis of SARS and with valid consent will be recruited.

Exclusion criteria

* Subjects with medical conditions that makes the prescription of study medications unsafe are excluded.

Design outcomes

Primary

Measure	Time frame
Development of severe SARS	Any time during the acute illness

Secondary

Measure	Time frame
Adverse events	Throughout the illness period
SARS-CoV Viral load	Throughout the illness period
Immunological profile	Throughout the illness period

Countries

China

Contacts

Primary ContactWai Cho Yu, Dr

yuwc@ha.org.hk(852) 2990 3737

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026